Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 door Caroline Robert (15032672)

Onderwerpen:

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 door Caroline Robert (15032672)

Onderwerpen:

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 door Caroline Robert (15032672)

Onderwerpen:

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 door Caroline Robert (15032672)

Onderwerpen:

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma door Jitske van den Bulk (17142147)

Onderwerpen:

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma door Jitske van den Bulk (17142147)

Onderwerpen:

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma door Jitske van den Bulk (17142147)

Onderwerpen:

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma door Jitske van den Bulk (17142147)

Onderwerpen:

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma door Jitske van den Bulk (17142147)

Onderwerpen:

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer door Christine Pich-Bavastro (16509238)

Onderwerpen:

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis door Nneoma Adaku (16991063)

Onderwerpen:

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors door Joseph Toker (15399882)

Onderwerpen:

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors door Joseph Toker (15399882)

Onderwerpen:

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis door Nneoma Adaku (16991063)

Onderwerpen: